Abcam, ab144483, (S)-AMPA (mM/ml), AMPA agonist

Size: 10mM / mL
MW 186.17 Da, Purity >98%. AMPA agonist. Achieve your results faster with highly validated, pure and trusted compounds.
Key facts
CAS number:83643-88-3,
Purity:>98%,
Form:SolidSee storage information,
Molecular weight:186.17 Da,
Molecular formula:C7H10N2O4,
PubChem:158397,
Nature:Synthetic,
Biochemical name:(S)-Ampa,
Biological description:AMPA agonist.,
Canonical smiles:CC1=C(C(=O)NO1)CC(C(=O)O)N,
Isomeric smiles:CC1=C(C(=O)NO1)C[C@@H](C(=O)O)N,
InChi:InChI=1S/C7H10N2O4/c1-3-4(6(10)9-13-3)2-5(8)7(11)12/h5H,2,8H2,1H3,(H,9,10)(H,11,12)/t5-/m0/s1,
InChiKey:UUDAMDVQRQNNHZ-YFKPBYRVSA-N,
IUPAC Name:(2S)-2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid

Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Store under desiccating conditions, The product can be stored for up to 12 months

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target encompasses several important glutamate receptors and cytochrome P450 enzymes including NMDAR2A NMDAR2B GluN2C and CYP2C9. These receptors and enzymes mediate synaptic transmission and drug metabolism. Glutamate receptors such as Glutamate Receptor 1 (AMPA subtype) play critical roles in excitatory neurotransmission in the central nervous system. They are structurally classified as ionotropic including AMPA and kainate (KA1 GRIK2/GluK2) subtypes and are mainly expressed in the brain. Cytochrome P450 enzymes like CYP2C9 CYP2C8 and others are expressed in the liver facilitating drug metabolism with a known molecular mass but can vary depending on the isoform.
Biological function summary
These targets are integral to neuronal signaling and metabolic processing. NMDARs known for their subunits NMDAR1 NMDAR3A and 3B interact as part of a larger receptor complex that modulates synaptic plasticity and memory formation. Glutamate receptors including GluA3 and GluA4 and their structures are essential for modulating synaptic strength. The cytochrome P450 family enzymes CYP2C19 and CYP2C12 contribute to the biotransformation of endogenous and exogenous compounds vital for maintaining homeostasis.
Pathways
These targets mediate key processes in glutamatergic signaling and detoxification. The glutamatergic synapse pathway involves AMPA and NMDA receptors like GluN2D critical for neurotransmission and synaptic plasticity. Moreover the xenobiotic metabolism pathway involves CYP450s such as CYP2C9 playing roles in drug metabolism. Proteins such as GRIK3/GluK3 and GluK5 interact in these pathways to ensure proper cellular function.
Disruptions in these targets associate with conditions like epilepsy and liver dysfunction. Glutamate receptor dysregulation including that of GluK1/GluK5 and similar subunits links to neurological disorders like epilepsy due to altered synaptic transmission. Cytochrome P450 mutations such as in CYP2C9 can result in compromised drug metabolism leading to liver-related issues and adverse drug reactions. These proteins through their roles represent key therapeutic targets for managing such conditions.